More than 7700 delegates registered for this year’s European Academy of Neurology Congress (1-4 July), with three quarters attending in person in Budapest, Hungary.
CGRP mAbs reduce headache and vertigo frequency, and migraine-related clinical burden, in patients with vestibular migraine (VM), according to data from a prospective observational cohort study evaluating the efficacy of erenumab, fremanezumab and galcanezumab. In the study of 50 patients with VM, 90% had ≥50% reduction in vertigo frequency at 18 months, 86% had ≥50% …
Read more »There is no upper age limit for use of anti-CGRP therapies in migraine, concluded researchers who investigated treatment effectiveness and safety in 114 patients over 65 years and 114 sex-matched controls under 55 years. Among cases treated with erenumab, fremanezumab or galcanezumab, 84.2% (96/114) were women, 79.8% (91/114) had chronic migraine and mean age was …
Read more »Real world evidence from the prospective, multicentre I-NEED study has confirmed that patients with migraine respond at least as well to CGRP mAbs (erenumab/fremanezumab/galcanezumab) in clinical practice as they do in clinical trials.1,2 Consecutive patients with high frequency episodic migraine (HFEM) or chronic migraine (CM) who had received more than one dose of a CGRP …
Read more »Further data on responder rates and quality of life measures from the ELEVATE trial continue to support the efficacy of atogepant 60 mg once daily in patients with episodic migraine who have failed two to four classes of conventional oral medication.1-3 Compared with placebo, significantly greater treatment effects were seen with atogepant (≥25%, ≥30%, ≥50%, …
Read more »Sustained reductions in monthly migraine days (MMD) up to 12 months of treatment with fremanezumab have been reported in the latest analysis of data from the real world PEARL study of 968 patients, two thirds with chronic migraine.1 More than half of patients achieved the primary endpoint of ≥50% reduction in MMD at six months, …
Read more »Galcanezumab, fremanezumab and erenumab have shown equal efficacy over 12 months in a prospective observational study of 140 patients with chronic or episodic migraine. Researchers reported mean reductions in monthly migraine days from baseline of -12.1 (-9.8,-14.5) with galcanezumab, -13.0 (-10.8,-15.2) with fremanezumab and -11.8 (-9.4,-14.1) with erenumab (all p<0.001 vs baseline). There were also …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
